Hubei Biocause Pharmaceutical (000627.SZ) subsidiary CHINA BEST life insurance company's accumulated premium income from January to August reached approximately 29.03 billion yuan.
Tianmao Group (000627.SZ) has announced that its subsidiary, Guohua Life Insurance Co., Ltd., a company controlled by the company, will follow according to...
Hubei Biocause Pharmaceutical (000627.SZ) announces that its controlling subsidiary, CHINA BEST Life Insurance Co., Ltd., is proceeding with business development in accordance with the overall strategy of "firmly transitioning for development, highlighting value growth, comprehensively improving capabilities, and moving towards a mature insurance enterprise". The company is focusing on value-based business, continuously promoting business structure optimization. From January 1, 2024 to August 31, 2024, the accumulated original insurance premium income is approximately 29.03 billion yuan.
Related Articles
HK Stock Market Move | CRO concept stocks led the gains: surging BD deals combined with rising wet-lab demand, clear signals of an upward industry cycle.
HK Stock Market Move | HUTCHMED (00013) rises over 3%, announces submission of New Drug Application to FDA for the combination therapy of ORPATHYS and TAGRISSO
China Galaxy Securities: The communications industry achieves self-reliance and self-strengthening through a "point-to-chain" approach, with scientific and technological innovation reaching a new level.
HK Stock Market Move | CRO concept stocks led the gains: surging BD deals combined with rising wet-lab demand, clear signals of an upward industry cycle.
HK Stock Market Move | HUTCHMED (00013) rises over 3%, announces submission of New Drug Application to FDA for the combination therapy of ORPATHYS and TAGRISSO
China Galaxy Securities: The communications industry achieves self-reliance and self-strengthening through a "point-to-chain" approach, with scientific and technological innovation reaching a new level.
